Logo

Principia Biopharma files for Initial Public Offering in the US

Share this

Principia Biopharma files for Initial Public Offering in the US

Shots:

  • Principia files IPO with $86mn having ticker PRNB
  • Principia’s lead product PRN1008 (BTKi) with Ph III & II for pemphigus and immune thrombocytopenic purpura respectively
  • In 2017- Principia collaborated with AbbVie for oral immunoproteasome inhibitors and with Sanofi for development of PRN2246 (BTKi

       Ref: Principia Biopharma | Image:  Pharmaletter

 

Click here to­ read the full press release 

Tags


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions